Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Tin Mesoporphyrin

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tin Mesoporphyrin

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mallinckrodt’s stannsoporfin turned away by FDA
    Mallinckrodt’s stannsoporfin turned away by FDA

    23 Aug 2018

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/mallinckrodts_stannsoporfin_turned_away_by_fda_1249940

    Selina McKee PHARMA TIMES
    23 Aug 2018
    Share Share
    After AdComm rejection, Mallinckrodt’s stannsoporfin gets stiff-armed at FDA
    After AdComm rejection, Mallinckrodt’s stannsoporfin gets stiff-armed at FDA

    22 Aug 2018

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/after-adcomm-rejection-mallinckrodt-s-stannsoporfin-gets-crl?mkt_tok=eyJpIjoiTURrNU0yTmpPV1l3TVdRMCIsInQiOiJYZ3lcL0E5V09MNGhQa0I3bjhOajBDZ3lcLytMcU1iMGRCczVjTVRJSVVSbW1kK2x3TXROVkQ1SUxkRE1vMm83dktRaVpmeklQU04wbVpYOWc2akdMOWJoSE5FczNKRFFGc3hKNkZcL1wvN01OdjV0MlVBZTlFWDVxam90YUFIcUNZZ24ifQ%3D%3D&mrkid=67302085

    Nick Paul Taylor FIERCE BIOTECH
    22 Aug 2018
    Share Share
    Mallinckrodt Reports on FDA Joint Advisory Committee Meeting for Stannsoporfin
    Mallinckrodt Reports on FDA Joint Advisory Committee Meeting for Stannsoporfin

    03 May 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mallinckrodt-reports-on-fda-joint-advisory-committee-meeting-for-stannsoporfin-for-the-treatment-of-newborns-at-risk-of-developing-severe-jaundice-300642605.html

    PR NEWSWIRE
    03 May 2018
    Share Share
    Mallinckrodt Receives FDA Acceptance of Stannsoporfin NDA Filing
    Mallinckrodt Receives FDA Acceptance of Stannsoporfin NDA Filing

    24 Feb 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mallinckrodt-receives-fda-acceptance-of-stannsoporfin-new-drug-application-filing-300603227.html

    PR NEWSWIRE
    24 Feb 2018
    Share Share
    Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin
    Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin

    05 Aug 2017

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/mallinckrodt-to-acquire-infacare-pharmaceutical-corporation-and-stannsoporfin-its-proprietary-therapy-in-late-stage-development-for-treatment-of-newborns-at-risk-for-developing-severe-jaundice-300499673.html

    PR NEWSWIRE
    05 Aug 2017
    Share Share
    InfaCare Announces the Successful Completion of its Phase IIB program
    InfaCare Announces the Successful Completion of its Phase IIB program

    24 Mar 2016

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/infacare-pharmaceutical-announces-the-successful-completion-of-its-phase-iib-multicenter-development-program-for-stannsoporfin-300241169.html

    PR NEWSWIRE
    24 Mar 2016
    Share Share